NCT05501860View on ClinicalTrials.gov

A Safety Study of of AG-920 Sterile Topical Ophthalmic Solution

PHASE3CompletedINTERVENTIONAL
Enrollment

249

Participants

Timeline

Start Date

July 30, 2022

Primary Completion Date

December 7, 2022

Study Completion Date

December 7, 2022

Conditions
Anesthesia, Local
Interventions
DRUG

AG-920

AG-920 Sterile Topical Ophthalmic Solution

DRUG

Placebo

Placebo Sterile Topical Ophthalmic Solution

Trial Locations (2)

78503

American Genomics Site 2, McAllen

92663

American Genomics Site 1, Newport Beach

Sponsors
All Listed Sponsors
lead

American Genomics, LLC

INDUSTRY